Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA

References

• SolèrMOmalizumab for severe allergic asthma: 7 years and open questionsRespiration201488215816124818580
   PubMed Web of Science ®Google Scholar
• WenzelSFordLPearlmanDDupilumab in persistent asthma with elevated eosinophil levelsN Engl J Med2013368262455246623688323
   PubMed Web of Science ®Google Scholar
• De BackerJWVosWGVinchurkarSCValidation of computational fluid dynamics in CT-based airway models with SPECT/CTRadiology2010257385486221084417
   PubMed Web of Science ®Google Scholar
• VinchurkarSBackerLDVosWHolsbekeCVBackerJDBackerWDA case series on lung deposition analysis of inhaled medication using functional imaging based computational fluid dynamics in asthmatic patients: effect of upper airway morphology and comparison with in vivo dataInhal Toxicol2012242818822260527
   PubMed Web of Science ®Google Scholar
• de RochefortLVialLFodilRIn vitro validation of computational fluid dynamic simulation in human proximal airways with hyperpolarized 3He magnetic resonance phase-contrast velocimetryJ Appl Physiol (1985)200710252012202317289906
   PubMed Web of Science ®Google Scholar
• De BackerJWVosWGDevolderAComputational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilationJ Biomech200841110611317698073
   PubMed Web of Science ®Google Scholar
• De BackerLAVosWDe BackerJVan HolsbekeCVinchurkarSDe BackerWThe acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function studyEur Respir J201240229830522183484
   PubMed Web of Science ®Google Scholar
• De BackerLAVosWGSalgadoRFunctional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPDInt J Chron Obstruct Pulmon Dis2011663764622162649
   PubMed Web of Science ®Google Scholar
• De BackerJVosWVan HolsbekeCEffect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patientsInt J Chron Obstruct Pulmon Dis2013856957924293993
   PubMed Web of Science ®Google Scholar
• De BackerWVosWVan HolsbekeCThe effect of roflumi-last in addition to LABA/LAMA/ICS treatment in COPD patientsEur Respir J201444252752924791831
   PubMed Web of Science ®Google Scholar
• ChongJPoolePLeungBBlackPNPhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20115CD00230921563134
   PubMed Web of Science ®Google Scholar
• BatemanEDRabeKFCalverleyPMARoflumilast with long-acting β2-agonists for COPD: influence of exacerbation historyEur Respir J201138355356021737553
   PubMed Web of Science ®Google Scholar
• RabeKFRoflumilast for the treatment of chronic obstructive pulmonary diseaseExpert Rev Respir Med20104554355520649375
   PubMedGoogle Scholar
• FabbriLMCalverleyPMAIzquierdo-AlonsoJLM2-127 and M2-128 Study GroupsRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• CalverleyPMARabeKFGoehringU-MM2-124 and M2-125 Study GroupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• De BackerJWVosWGVinchurkarSCValidation of computational fluid dynamics in CT-based airway models with SPECT/CTRadiology2010257385486221084417
   PubMed Web of Science ®Google Scholar
• JanssensWLiuYLiuDQuality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT(®))Respir Med201310791409141623714653
   PubMed Web of Science ®Google Scholar
• FranciosiLGDiamantZBannerKHEfficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trialsLancet Respir Med20131971472724429275
   PubMed Web of Science ®Google Scholar
• WatzHMistrySJLazaarALSafety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPDPulm Pharmacol Ther201326558859523701917
   PubMed Web of Science ®Google Scholar
• GiembyczMANewtonRHow phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotypeClin Chest Med201435120321724507847
   PubMed Web of Science ®Google Scholar
• YuTFainKBoydCMBenefits and harms of roflumilast in moderate to severe COPDThorax201469761662224347460
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMAGoehringU-MBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• WedzichaJABrillSEAllinsonJPDonaldsonGCMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBMC Med20131118123945277
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMSeemungalTARThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar
• CoxsonHOLeipsicJParragaGSinDDUsing pulmonary imaging to move COPD beyond FEV1Am J Respir Crit Care Med2014190213514424873985
   PubMed Web of Science ®Google Scholar
• ChapmanKRFogartyCMPeckittCDelivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPDInt J Chron Obstruct Pulmon Dis2011635336321760722
   PubMed Web of Science ®Google Scholar
• WeuthenTRoederSBrandPMüllingerBScheuchGIn vitro testing of two formoterol dry powder inhalers at different flow ratesJ Aerosol Med200215329730312396417
   PubMedGoogle Scholar
• HoeSTrainiDChanH-KYoungPMMeasuring charge and mass distributions in dry powder inhalers using the electrical next generation impactor (eNGI)Eur J Pharm Sci2009382889419559086
   PubMed Web of Science ®Google Scholar
• TarsinWYPearsonSBAssiKHChrystynHEmitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmaticsInt J Pharm20063161–213113716584855
   PubMed Web of Science ®Google Scholar
• De BackerWDevolderAPoliGLung Deposition of BDP/Formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patientsJ Aerosol Med Pulm Drug Deliv201023313714820109122
   PubMed Web of Science ®Google Scholar
• TrukhachevaLAGorpinchenkoNVDementyevSPComparative analysis of the in vitro equivalence of the metered aerosol inhalers Seretide and Tevacomb conducted by the new generation impactor nextPediatr Pharmacol2012957074
   Google Scholar
• VestboJTanLAtkinsonGWardJUK-500,001 Global Study TeamA controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPDEur Respir J20093351039104419213793
   PubMed Web of Science ®Google Scholar